Abstract
<jats:p>Surrogate endpoints, or measures used in place of the true outcome of interest, have relevance across multiple disease areas. The Prentice Criteria, proposed in 1989, assess surrogacy by evaluating how the treatment's effect on the true outcome operates through the potential surrogate. Using the A4 Study of solanezumab, we evaluate multiple formulations of the Prentice Criteria using causal mediation. We estimated direct and indirect effects of solanezumab on cognitive decline through cerebral amyloid across different, but reasonable, measures of exposure, mediator, outcome, and covariate adjustment. Unsurprisingly given that solanezumab did not show benefit, estimated indirect effects were close to zero. These results provide little evidence of meaningful mediation for memory and global cognition, but precision varied substantially. Confidence interval widths varied by up to a factor of 17 across specifications. Causal mediation analysis of individual-level randomized trial data may contribute to quantitative surrogate endpoint evaluation, but our findings indicate this is only the case when analytic choices are biologically justified, prespecified, and interpreted with attention to uncertainty.</jats:p>